FDA Guidance for Clinical Investigators, Sponsors and IRBs Regarding Adverse Event Reporting in GCP Regulated Environments

November 15, 2019
Previous
Noncompliance to FDA Quality Standards: What's the Risk to Executives?
Noncompliance to FDA Quality Standards: What's the Risk to Executives?

Find out what safeguards upper management should consider and what steps must be taken to ensure consistent...

Next Flipbook
Ensuring the Adequacy of the Informed Consent Process in GCP Regulated Environments
Ensuring the Adequacy of the Informed Consent Process in GCP Regulated Environments

This white paper discusses what an Informed Consent Form is and its importance in clinical trials.